Breast cancer is the most common cancer in women worldwide, with more than two million new cases diagnosed in 2018. More: Eli Lilly announces Verzenio survival benefit Source: News
read moreIt has also announced the appointment of the company’s new general manager, Craig Bowen. More: Neuraxpharm launches first products in UK Source: News
read moreThe partnership will focus on the analysis of the circulating proteome of advanced pancreatic cancer patients treated with IMM-10. More: Biodesix, Immodulon team up for pancreatic cancer treatment Source: News
read moreAmgen is working to grow sales for new meds, but in the second quarter, costly losses of exclusivity for Sensipar and Neulasta hurt the drugmaker. More: Amgen sales slide as copies dig into Sensipar, Neulasta Source: fierce
read moreCelgene has provided Bristol-Myers Squibb investors an updated look at the business they’re buying—and not getting. Myeloma drugs Revlimid and Pomalyst and to-be-sold Otezla all delivered double-digit growth in the second quarter. More: Celgene's new triple-combo FDA nods shift Revlimid,
read moreEli Lilly’s CGRP migraine prevention drug Emgality is in a heated market share race with Amgen’s Aimovig and Teva’s Ajovy, but in the second quarter, it gained some steam. More: Lilly's Emgality powers ahead with 'best-in-class' CGRP access Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals